B. Riley Financial Has Lowered Expectations for OptimizeRx (NASDAQ:OPRX) Stock Price

OptimizeRx (NASDAQ:OPRX) had its target price cut by analysts at B. Riley Financial from $11.00 to $10.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial’s price target would suggest a potential upside of 117.44% from the stock’s current price.

A number of other equities research analysts have also weighed in on the company. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Roth Mkm lowered their price objective on OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Stephens lowered their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday. Lake Street Capital set a $11.00 price target on OptimizeRx in a research note on Wednesday. Finally, UBS Group set a $10.00 price target on OptimizeRx in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and an average target price of $13.43.

OptimizeRx Stock Down 27.5%

OptimizeRx stock traded down $1.74 during midday trading on Wednesday, reaching $4.60. The company’s stock had a trading volume of 1,661,082 shares, compared to its average volume of 451,839. OptimizeRx has a fifty-two week low of $4.60 and a fifty-two week high of $22.25. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. The company has a market cap of $86.28 million, a P/E ratio of 17.67 and a beta of 1.19. The business has a 50-day simple moving average of $6.59 and a 200-day simple moving average of $10.94.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%.The company had revenue of $19.84 million for the quarter, compared to analysts’ expectations of $18.35 million. On average, research analysts expect that OptimizeRx will post 0.5 earnings per share for the current fiscal year.

OptimizeRx declared that its Board of Directors has authorized a stock buyback plan on Thursday, March 5th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its holdings in shares of OptimizeRx by 22.3% during the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after purchasing an additional 102,661 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of OptimizeRx by 131.7% during the 1st quarter. Principal Financial Group Inc. now owns 63,790 shares of the company’s stock worth $401,000 after buying an additional 36,259 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of OptimizeRx during the 1st quarter worth $85,000. Aaron Wealth Advisors LLC acquired a new stake in shares of OptimizeRx during the 1st quarter worth $66,000. Finally, Millennium Management LLC acquired a new stake in shares of OptimizeRx during the 4th quarter worth $535,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.